Tarsus Pharmaceuticals
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
15440 Laguna Canyon Rd Ste 160, Irvine, ...Phone Number
(949) 418-1801Website
www.tarsusrx.comRevenue
$535.1 MillionStock Symbol
TARSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
6
1
1
1
2
1
About Tarsus Pharmaceuticals
Founded in 2017, Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for a range of diseases. The company's lead product is a topical ophthalmic that targets an underlying cause of blepharitis. Tarsus is headquartered in Irvine, California.Explore more
Tarsus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tarsus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Tarsus Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Tarsus Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Tarsus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Tarsus Pharmaceuticals recently announced quarterly report
Check if Tarsus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Tarsus Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once Tarsus Pharmaceuticals has new funding data
Click to see if Tarsus Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Tarsus Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Tarsus Pharmaceuticals
Compare insights from companies similar to Tarsus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tarsus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tarsus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals financials insights
Gather financial insights about Tarsus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$60M
2022
Debt
$175M
Tarsus Pharmaceuticals Tech Stack
A closer look at the technologies used by Tarsus Pharmaceuticals
See more technologies
Most Recent Scoops
Open Position
Project
Tarsus Pharmaceuticals has announced the publication of an abstract demonstrating that approximately 70% of patients with hordeola or chalazia also have Demodex blepharitis, identifying an incremental patient population of 1 million to 2 million beyond the previously estimated total addressable market.
Medical Research
Earnings
Tarsus Pharmaceuticals has updated its peak sales guidance to a $2 billion-plus opportunity, up from the initial launch estimate of $1 billion, based on data gathered since the product's commercial introduction.
Sales
Hiring Plans
Tarsus Pharmaceuticals has more open roles in Operations than it has had at any time in the past 12 months. Technologies mentioned include: Remote.
Hiring Plans
Earnings
Earnings, Financial Planning, Finance, Financial Strategy
Tarsus Pharmaceuticals News & Media
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced a new partnership with John Cena to raise awareness of Demodex blepharitis, a common but often overlooked eyelid disease caused by microscopic mites that live in and around the eyelashes. Cena’s story reflects the experience of millions who live with symptoms for years before seeking care and receiving a proper diagnosis.Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tarsus Pharmaceuticals, Inc. (TARS) Bank of America Global Healthcare Conference 2026 May 12, 2026 6:40 PM EDTCompany ParticipantsJeffrey S.Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
Generated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85% year-over-year
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tarsus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 2017, Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for a range of diseases. The company's lead product is a topical ophthalmic that targets an underlying cause of blepharitis. Tarsus is headquartered in Irvine, California.... Read More
